{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02257567\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["polatuzumab vedotin"],["polatuzumab vedotin","obinutuzumab","bendamustine"]],"indication":"relapsed/refractory follicular or diffuse large B-cell lymphoma","name":"GO29365","nct_id":"NCT02257567","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=go29365-nct02257567. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.","label":"Arm A (Phase II Randomization): Polatuzumab+BR in FL","type":"EXPERIMENTAL"},{"description":"Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.","label":"Arm B (Phase II Randomization): BR in FL","type":"ACTIVE_COMPARATOR"},{"description":"Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.","label":"Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL","type":"EXPERIMENTAL"},{"description":"Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.","label":"Arm D (Phase II Randomization): BR in DLBCL","type":"ACTIVE_COMPARATOR"},{"description":"Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.","label":"Arm E (Phase II Expansion): Polatuzumab+BG in FL","type":"EXPERIMENTAL"},{"description":"Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.","label":"Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL","type":"EXPERIMENTAL"},{"description":"Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.","label":"Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL","type":"EXPERIMENTAL"},{"description":"Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.","label":"Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL","type":"EXPERIMENTAL"},{"description":"Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.","label":"Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL","type":"EXPERIMENTAL"},{"description":"Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.","label":"Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL","type":"EXPERIMENTAL"},{"description":"In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.","label":"Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL","type":"EXPERIMENTAL"},{"description":"In this NF cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.","label":"Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2021-10-21","type":"ACTUAL"},"conditions":["Lymphoma"],"enrollment":{"count":331,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Bendamustine","otherNames":["Treanda; Ribomustin; Levact"],"type":"DRUG"},{"name":"Obinutuzumab","otherNames":["GA101; Gazyva; Gazyvaro"],"type":"DRUG"},{"name":"Polatuzumab vedotin (Liquid)","otherNames":["DCDS4501A"],"type":"DRUG"},{"name":"Rituximab","otherNames":["Rituxan; MabThera"],"type":"DRUG"},{"name":"Polatuzumab vedotin (Lyophilized)","otherNames":["DCDS4501S"],"type":"DRUG"}],"last_update":"2022-11-14","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2021-10-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase Ib: Percentage of Participants With Adverse Events (AEs)","timeFrame":"From the study start up to the end of the study (up to approximately 84 months)"},{"measure":"Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs","timeFrame":"From Month 37 to Month 84 (up to approximately 47 months)"},{"measure":"Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin","timeFrame":"Baseline up to approximately Month 24"},{"measure":"Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab","timeFrame":"Baseline up to approximately Month 24"},{"measure":"Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized)","timeFrame":"From Month 37 to Month 84 (up to approximately 47 months)"},{"measure":"Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)","timeFrame":"6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)"},{"measure":"Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC","timeFrame":"6-8 weeks after Cycle 6, Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)"},{"measure":"Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized)","timeFrame":"Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks"},{"measure":"Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized)","timeFrame":"Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks"},{"measure":"Arm G (Phase II NF Cohort): Systemic Clearance (CL) of Polatuzumab Vedotin (Lyophilized)","timeFrame":"Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks"},{"measure":"Arm G (Phase II NF Cohort): Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin (Lyophilized)","timeFrame":"Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks"}],"references":[{"citation":"Jemaa S, Ounadjela S, Wang X, El-Galaly TC, Kostakoglu L, Knapp A, Ku G, Musick L, Sahin D, Wei MC, Yin S, Bengtsson T, De Crespigny A, Carano RAD. Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose-Positron Emission Tomography. J Clin Oncol. 2024 Sep 1;42(25):2966-2977. doi: 10.1200/JCO.23.01978. Epub 2024 Jun 6.","pmid":"38843483","type":"DERIVED"},{"citation":"Bosch F, Kuruvilla J, Vassilakopoulos TP, Maio DD, Wei MC, Zumofen MB, Nastoupil LJ. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):105-121. doi: 10.1016/j.clml.2023.09.007. Epub 2023 Sep 28.","pmid":"37981564","type":"DERIVED"},{"citation":"Herrera AF, Tracy S, Croft B, Opat S, Ray J, Lovejoy AF, Musick L, Paulson JN, Sehn LH, Jiang Y. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood Adv. 2022 Mar 22;6(6):1651-1660. doi: 10.1182/bloodadvances.2021006415.","pmid":"35086141","type":"DERIVED"},{"citation":"Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, Kim TM, McMillan A, Ozcan M, Safar V, Salles G, Ku G, Hirata J, Chang YM, Musick L, Matasar MJ. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022 Jan 25;6(2):533-543. doi: 10.1182/bloodadvances.2021005794.","pmid":"34749395","type":"DERIVED"},{"citation":"Betts KA, Thuresson PO, Felizzi F, Du EX, Dieye I, Li J, Schulz M, Masaquel AS. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma. J Comp Eff Res. 2020 Oct;9(14):1003-1015. doi: 10.2217/cer-2020-0057. Epub 2020 Oct 8.","pmid":"33028076","type":"DERIVED"},{"citation":"Shi R, Lu T, Ku G, Ding H, Saito T, Gibiansky L, Agarwal P, Li X, Jin JY, Girish S, Miles D, Li C, Lu D. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2020 Sep;86(3):347-359. doi: 10.1007/s00280-020-04119-8. Epub 2020 Aug 8.","pmid":"32770353","type":"DERIVED"},{"citation":"Lu T, Gibiansky L, Li X, Li C, Shi R, Agarwal P, Hirata J, Miles D, Chanu P, Girish S, Jin JY, Lu D. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2020 Dec;61(12):2905-2914. doi: 10.1080/10428194.2020.1795154. Epub 2020 Jul 24.","pmid":"32705923","type":"DERIVED"},{"citation":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6.","pmid":"31693429","type":"DERIVED"}],"start_date":{"date":"2014-10-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT02257567"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/go29365-nct02257567"}